Serlopitant

Serlopitant is a drug that was under development for the treatment of conditions such as pruritus (itching), psoriasis, and cough. It acts as a neurokinin 1 receptor antagonist, blocking the action of substance P, a neurotransmitter thought to mediate pain and itching.

History[edit | edit source]

Serlopitant was developed by Merck & Co. and licensed to Menlo Therapeutics in 2012. In 2020, it failed to meet the primary endpoints in two Phase 3 clinical trials for pruritus associated with prurigo nodularis.

Mechanism of action[edit | edit source]

Serlopitant is a small-molecule, highly selective antagonist of the neurokinin 1 (NK1) receptor. The NK1 receptor is a G-protein coupled receptor located in key areas of the central and peripheral nervous system. Substance P, the endogenous ligand for the NK1 receptor, is involved in many physiological processes, including the transmission of pain, regulation of blood pressure, and inflammatory responses. By blocking the action of substance P, serlopitant may reduce itching, inflammation, and pain.

Clinical trials[edit | edit source]

Serlopitant has been evaluated in several clinical trials for various indications. In 2020, two Phase 3 trials for pruritus associated with prurigo nodularis failed to meet their primary endpoints. However, earlier Phase 2 studies showed promising results in reducing pruritus in patients with atopic dermatitis, psoriasis, and chronic pruritus of unknown origin.

Side effects[edit | edit source]

The most common side effects reported in clinical trials were fatigue, diarrhea, and nausea. These were generally mild and transient.

Future development[edit | edit source]

Despite the failure of the Phase 3 trials, Menlo Therapeutics has stated that they will continue to evaluate the potential of serlopitant in other indications.

See also[edit | edit source]

Serlopitant Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.